Datapoint: Cigna Adds Humira Biosimilars to Formulary

Cigna on July 10 said it will add three new Humira biosimilars — Boehringer Ingelheim’s Cyltezo and Sandoz’s Hyrimoz and Adalimumab-adaz (the unbranded equivalent of Hyrimoz) — to its national preferred, standard, performance, and legacy commercial formularies controlled by Cigna Pharmacy Management. The products will be preferred at parity with Humira. The company also said it will cover Organon’s Hadlima as a preferred drug on its value, advantage, and total savings formularies. Cigna Pharmacy Management, which handles drug benefits for Cigna Healthcare, currently manages 11.2 million pharmacy lives. Humira is a preferred product that requires utilization management, such as step therapy and/or prior authorization, for 67% of Cigna’s pharmacy lives.

SOURCE: MMIT Analytics, as of 7/12/23

0 Comments
Jinghong Chen

Jinghong Chen Reporter

Jinghong produces infographics and data stories on health insurance and specialty pharmacy for AIS Health. She graduated from Missouri School of Journalism with a focus on data journalism and international reporting. Before joining AIS in 2018, she worked at WBEZ, Al Jazeera English and The New York Times Chinese.

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 21

Datapoint: Cigna, HelloFresh Partner on Meal Kit Benefits

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 20

Datapoint: SCAN, CareOregon Nix Merger Plans

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 15

Datapoint: AbbVie Completes ImmunoGen Deal

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today